OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
April 02, 2021
The inhaled route of administration for biologics is experiencing renewed interest, particularly in light of the COVID-19 pandemic.
September 01, 2020
Current and newer biologic modalities pose increasingly complex challenges to the detection and characterization of protein aggregates.
July 02, 2020
Manufacturers and the US government are investing heavily in traditional and non-traditional forms and materials to ensure supplies of containers and delivery devices for COVID-19 treatments and vaccines.
RNA is easier to manipulate than DNA but challenging to deliver to the right cells.
April 14, 2020
With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.
April 01, 2020
Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.
As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.
March 01, 2020
Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.
October 24, 2019
CHMP has recommended that Ervebo (rVSVΔG-ZEBOV-GP), a vaccine for active immunization against Ebola, be granted conditional marketing authorization in the EU.
October 17, 2019
On Tuesday, Nov. 5, 2019, Karima Yadi from Becton Dickinson & Co. will present the challenges of using, and necessity for, shorter needles and integrated systems with high viscosity drugs, such as biologics, to improve the patient experience at CPhI Worldwide.